Get the Stockscreener App
30.85
1.12%
-0.35
Crinetics Pharmaceuticals Inc stock is traded at $30.85, with a volume of 539.12K.
It is down -1.12% in the last 24 hours and down -1.25% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$31.20
Open:
$30.74
24h Volume:
539.12K
Relative Volume:
0.58
Market Cap:
$3.10B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-8.2708
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-6.74%
1M Performance:
-1.25%
6M Performance:
-44.28%
1Y Performance:
-31.00%
1-Day Range:
$30.62
$31.30
1-Week Range:
$30.62
$33.35
52-Week Range:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
30.85 | 3.10B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan
Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha
Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Research Analysts Offer Predictions for CRNX FY2026 Earnings - Defense World
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Crinetics Strengthens Team with $2.4M in Equity Grants: 74,000 Stock Options Plus RSUs for New Talent - Stock Titan
(CRNX) Trading Report - news.stocktradersdaily.com
Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India
(CRNX) Investment Report - news.stocktradersdaily.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 | CRNX Stock News - GuruFocus
Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
BNP Paribas Financial Markets Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation? - Yahoo Finance
CRNX Achieves FDA Orphan Drug Status for Paltusotine in Carcinoi - GuruFocus
Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - MSN
Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - The Manila Times
New Clinical Data: Oral Drug Paltusotine Could Replace Injectable Acromegaly TreatmentsKey AACE 2025 Findings - Stock Titan
Analysts Set Expectations for CRNX FY2025 Earnings - Defense World
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and Pivotal Launches on the Horizon - GuruFocus
Earnings call transcript: Crinetics Pharma stock rises after Q1 2025 results - Investing.com Nigeria
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics (CRNX) Exceeds Revenue Expectations, Advances Key Proj - GuruFocus
Crinetics Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $0.4M, EPS Misses at -$1.04 - GuruFocus
Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position - Nasdaq
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus
Viracta Therapeutics (NASDAQ:VIRX) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Review - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings - GuruFocus
Closing Figures: Crinetics Pharmaceuticals Inc (CRNX)’s Negative Finish at 30.52, Down -9.30 - DWinneX
August 15th Options Now Available For Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):